Gamida Cell Ltd. (GMDA)

NASDAQ: GMDA · IEX Real-Time Price · USD
2.36
0.02 (0.85%)
At close: May 16, 2022 4:00 PM
2.35
-0.01 (-0.42%)
After-hours:May 16, 2022 5:15 PM EDT
Market Cap141.47M
Revenue (ttm)n/a
Net Income (ttm)-91.98M
Shares Out59.95M
EPS (ttm)-1.52
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume127,265
Open2.35
Previous Close2.34
Day's Range2.32 - 2.45
52-Week Range2.10 - 6.94
Beta1.62
AnalystsBuy
Price Target15.30 (+548.3%)
Earnings DateMay 10, 2022

About GMDA

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Ho...

IndustryBiotechnology
IPO DateOct 26, 2018
Employees166
Stock ExchangeNASDAQ
Ticker SymbolGMDA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for GMDA stock is "Buy." The 12-month stock price forecast is 15.3, which is an increase of 548.31% from the latest price.

Price Target
$15.3
(548.31% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Gamida Cell Reports First Quarter 2022 Financial Results and Provides Company Update

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today pr...

6 days ago - Business Wire

Gamida Cell Presents New Data from NAM-Enabled Genetically Modified Natural Killer (NK) Pipeline at International Soc...

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with solid and hematological cancers and other serious diseases, today ...

1 week ago - Business Wire

Gamida Cell Announces the Date of Its First Quarter 2022 Financial Results and Webcast

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will host a c...

1 week ago - Business Wire

Gamida Cell Posts Updated Omidubicel Data In Blood Cancer Patients

Gamida Cell Ltd (NASDAQ: GMDA) announced that updated infection data on omidubicel compared to umbilical cord blood transplantation (UCB) was shared at the Transplantation & Cellular Therapy ASTCT and C...

2 weeks ago - Benzinga

Gamida Cell Presents Updated One-Year Post-Transplant Follow Up Data from Phase 3 Study of Omidubicel at 2022 Transpl...

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with solid and hematological cancers and other serious diseases, today ...

2 weeks ago - Business Wire

Gamida Cell Shares Jump On FDA Nod To Cell Therapy Trial In Blood Cancer Settings

The FDA has signed off and removed the clinical hold for a cryopreserved formulation of Gamida Cell Ltd's (NASDAQ: GMDA) GDA-201, an off-the-shelf cell therapy candidate for follicular and diffuse large...

2 weeks ago - Benzinga

5 Hot Penny Stocks To Watch With Premarket Momentum & News

Why are these penny stocks moving in the stock market today? The post 5 Hot Penny Stocks To Watch With Premarket Momentum & News appeared first on Penny Stocks to Buy, Picks, News and Information | Penn...

Other symbols:IMPPJZXNOBSVRDBX
2 weeks ago - PennyStocks

Gamida Cell Announces FDA Clearance of IND and Removal of Clinical Hold for NK Cell Therapy Candidate GDA-201

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today an...

2 weeks ago - Business Wire

Gamida Cell Presents Updated Omidubicel Data During Best Abstract Award Session at 2022 Transplantation & Cellular Th...

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with solid and hematological cancers and other serious diseases, today ...

3 weeks ago - Business Wire

Gamida Cell Announces Results of New Health Economic and Outcome Study Reporting Improved Health Equity and Health Ou...

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with solid and hematological cancers and other serious diseases, today ...

3 weeks ago - Business Wire

Gamida Cell to Present Corporate Highlights and Participate in Panel Discussion at the Needham Healthcare Conference

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with solid and hematological cancers and other serious diseases, announ...

1 month ago - Business Wire

Gamida Cell Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, today provided a business update and reported financi...

2 months ago - Business Wire

Gamida Cell to Present Corporate Highlights at the Oppenheimer 32nd Annual Healthcare Conference

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that company management will p...

2 months ago - Business Wire

Gamida Cell Announces the Date of Its Fourth Quarter and Full Year 2021 Financial Results and Webcast

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will host a c...

2 months ago - Business Wire

Is a Surprise Coming for Gamida (GMDA) This Earnings Season?

Gamida (GMDA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

2 months ago - Zacks Investment Research

5 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates

Let us take a look at some drug/biotech stocks, EVLO, GMDA, APLS, MRTX and ITOS, which are poised to beat on fourth-quarter earnings.

Other symbols:APLSEVLOITOSMRTX
2 months ago - Zacks Investment Research

Gamida Cell Shares Surge On Rolling Omidubicel Marketing Application In US

Gamida Cell Ltd GMDA has initiated the Biologics License Application (BLA) rolling submission process with the FDA for omidubicel, in patients with blood cancers needing stem cell transplant.  Get the I...

3 months ago - Benzinga

Gamida Cell Initiates Rolling Submission of Biologics License Application for Omidubicel

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, today announced that it has initiated the Biologics L...

3 months ago - Business Wire

Gamida Cell Announces Appointment of Anat Cohen-Dayag and Naama Halevi-Davidov to its Board of Directors

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, today announced the addition of Anat Cohen-Dayag, Ph....

3 months ago - Business Wire

Cell Therapy-Focused Gamida Plans To Cut 10% Of Staff

Gamida Cell Ltd GMDA will terminate 10% of its staff as part of an effort to extend its cash runway for a planned filing for cell therapy omidubicel with the FDA. [ALERT] Nic Chahine shares his Bear Mar...

3 months ago - Benzinga

Gamida Cell Provides Key Program Updates and 2022 Financial Guidance

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, today provided key program and business updates. Init...

3 months ago - Business Wire

Popular Penny Stocks to Know About as January Ends

Can these penny stocks make gains moving forward? The post Popular Penny Stocks to Know About as January Ends appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols:CFMS
3 months ago - PennyStocks

Gamida (GMDA) Up on Omidubicel BLA Rolling Submission Plan

The FDA agrees to the initiation of rolling submission of Gamida's (GMDA) BLA for its lead blood cancer candidate, omidubicel. The stock rises more than 22% on in response.

3 months ago - Zacks Investment Research

Hot Penny Stocks: What's Moving VVOS, GMDA and SBEV Higher Today?

Several penny stocks are on the move Wednesday and we're diving into the hot news behind that momentum with a quick dive into the space. The post Hot Penny Stocks: What's Moving VVOS, GMDA and SBEV High...

Other symbols:SBEVVVOS
3 months ago - InvestorPlace

4 Penny Stocks To Watch After DWAC Stock Wakes Up Small Caps

Small cap stocks to watch after Trump bump hits penny stocks The post 4 Penny Stocks To Watch After DWAC Stock Wakes Up Small Caps appeared first on Penny Stocks to Buy, Picks, News and Information | Pe...

Other symbols:PHUNSBEVVVOS
3 months ago - PennyStocks